Scarica l'app Stockscreener
0.8992
0.33%
-0.003
Dopo l'orario di chiusura:
.90
0.0008
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9022
Aprire:
$0.89
Volume 24 ore:
505.58K
Relative Volume:
0.60
Capitalizzazione di mercato:
$49.21M
Reddito:
-
Utile/perdita netta:
$-40.56M
Rapporto P/E:
-0.7685
EPS:
-1.17
Flusso di cassa netto:
$-35.28M
1 W Prestazione:
-4.95%
1M Prestazione:
-0.55%
6M Prestazione:
-23.80%
1 anno Prestazione:
-37.99%
Intervallo 1D:
$0.855
$0.8992
Intervallo di 1 settimana:
$0.855
$1.01
Portata 52W:
$0.703
$2.20
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Nome
Pds Biotechnology Corporation
Settore
Industria
Telefono
800-208-3343
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Confronta PDSB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.8992 | 49.37M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-01 | Iniziato | B. Riley Securities | Buy |
| 2021-06-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-09 | Iniziato | Noble Capital Markets | Outperform |
| 2019-10-24 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
PDS Biotech secures patent for cancer immunotherapy PDS0101 By Investing.com - Investing.com Nigeria
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection - TipRanks
PDS Biotech secures patent for cancer immunotherapy PDS0101 - Investing.com
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - The Manila Times
New PDS0101 patent extends U.S. market protection toward 20 years - Stock Titan
Aug Macro: Can PDS Biotechnology Corporation stock outperform in a bear market2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Miss: Can STRW maintain sales growthMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Growth Value: Is PDS Biotechnology Corporation trading at a discount - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
PDS Biotechnology Corporation (PDSB) stock: surges as FDA protocol amendment aims for accelerated approval - parameter.io
PDS Biotech stock soars after FDA meeting provides accelerated approval path By Investing.com - Investing.com South Africa
PDS Biotech stock soars after FDA meeting provides accelerated approval path - Investing.com Nigeria
PDS Biotech Announces FDA Alignment on Use of Progression Free Survival as Primary Endpoint - marketscreener.com
PDS Biotech submits amended protocol for phase 3 cancer trial By Investing.com - Investing.com India
PDS Biotech Files Amended Protocol for Phase 3 VERSATILE-003 Trial to Seek Accelerated Approval of PDS0101 - Quiver Quantitative
Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan
How institutional buying supports PDS Biotechnology Corporation stockJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - Улправда
Is PDS Biotechnology Corporation stock resilient to inflation2025 Earnings Impact & AI Forecasted Entry/Exit Points - ulpravda.ru
Does PDS Biotechnology Corporation stock trade at a discount to peersM&A Rumor & Verified Short-Term Trading Plans - Улправда
PDS Biotechnology (NASDAQ:PDSB) Trading 5% Higher – Here’s Why - Defense World
Aug Sentiment: How PDS Biotechnology Corporation stock trades during market volatility2025 Pullback Review & Entry and Exit Point Strategies - Улправда
How interest rate cuts could boost PDS Biotechnology Corporation stockSell Signal & Reliable Entry Point Alerts - Улправда
Guidance Update: Does PDS Biotechnology Corporation stock trade at a discount to peersMarket Volume Report & Verified Momentum Watchlists - Улправда
Can PDS Biotechnology Corporation stock sustain institutional interest2025 Pullback Review & Weekly Chart Analysis and Trade Guides - DonanımHaber
Will PDS Biotechnology Corporation stock continue upward momentum2025 Institutional Moves & Daily Market Momentum Tracking - bolumsonucanavari.com
How PDS Biotechnology Corporation stock performs after earningsJuly 2025 Update & Capital Efficiency Focused Ideas - DonanımHaber
Aug Spikes: How supply chain issues affect PDS Biotechnology Corporation stockWeekly Market Outlook & Real-Time Volume Trigger Notifications - moha.gov.vn
PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened - Defense World
Stocks of PDS Biotechnology Corporation (PDSB) are poised to climb above their peers - setenews.com
PDS Biotech secures new patent for cancer immunotherapy in Japan By Investing.com - Investing.com Australia
PDS Biotechnology Secures New Patent for PDS0101 - TipRanks
PDS Biotech secures new patent for cancer immunotherapy in Japan - Investing.com
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - The Manila Times
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - sharewise.com
EPS Watch: How interest rate cuts could boost PDS Biotechnology Corporation stockTrade Risk Report & Precise Buy Zone Tips - moha.gov.vn
How supply chain issues affect PDS Biotechnology Corporation stock2025 Macro Impact & AI Powered Market Trend Analysis - Newser
A better buy-in window may exist right now for PDS Biotechnology Corporation (PDSB) - setenews.com
Is PDS Biotechnology Corporation stock ready for breakoutOptions Play & Real-Time Volume Spike Alerts - Newser
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech announces scheduling of Type C meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - moha.gov.vn
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - moha.gov.vn
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
Pds Biotechnology Corporation Azioni (PDSB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):